Researchers are especially interested in what happens when three signaling pathways activate at once and how that compares to single- and dual-receptor approaches
Manne-Goehler, J., Teufel, F
Furthermore, the Endocrine Societys obesity guideline recommends that patients with obesity in the absence of diabetes should discontinue weight-loss medications if safety or tolerability issues arise, and consider other therapeutic options
Patients with needle anxiety often prefer oral options, accepting the slightly higher monthly investment
GLP-1RAs may represent a class effect, offering dual metabolic and immunomodulatory benefits with long-term impact on comorbidities
Participants received tirzepatide or placebo for 72 weeks (Jastreboff et al., NEJM 2022)